Merus NV

Merus NV’s bispecific antibody oncology pipeline and recent ownership shift by Genmab spark investor interest, promising growth amid evolving biotech dynamics.

Merus NV, a clinical-stage immuno-oncology company, is pioneering the development of bispecific antibody therapeutics to treat and potentially cure cancer patients.

Merus NV, a clinical-stage immuno-oncology company, plans to expand its operations through a proposed public offering of common shares to accelerate its mission to combat cancer.

Merus NV, a clinical-stage immuno-oncology company, continues to make significant strides in developing bispecific antibody therapeutics for cancer treatment.

Merus NV, a clinical-stage immuno-oncology company, has experienced positive developments, including analyst upgrades and promising Phase 2 clinical trial results, driving its stock price up.

Merus NV’s stock price surges 30% after positive clinical trial results for its bispecific antibody petosemtamab, boosting investor confidence in the company’s potential to revolutionize cancer treatment.

Merus NV’s stock surges 30% after positive interim results from its Phase 2 trial of petosemtamab in combination with pembrolizumab for head and neck cancer treatment.

Merus NV’s stock surged 30% after positive interim results from a Phase 2 clinical trial of its cancer treatment, petosemtamab, showed promising efficacy and durability.

Merus NV’s phase 2 trial data shows promising results for its bispecific antibody treatment, potentially positioning it as a new standard of care for head and neck squamous cell carcinoma.

Merus NV, a clinical-stage immuno-oncology company, will present at the BofA Securities 2025 Health Care Conference, highlighting its bispecific antibody therapeutics and providing an update on its financial stability and pipeline progress.